Teriflunomide

Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “2024 was a year of significant outperformance and growth for TG, highlighted by the strong adoption of BRIUMVI for adult patients with relapsing forms of multiple sclerosis, which surpassed our initial expectations. Additionally, we made meaningful progress in strengthening our BRIUMVI patent portfolio through 2042, launching new clinical trials, including for subcutaneous BRIUMVI, and advancing our pipeline. These accomplishments provide a solid foundation as we look toward continued success in 2025.” 2024 Highlights & Recent Developments BRIUMVI® (ublituximab-xiiy) Commercialization BRIUMVI United States (U.S.) net product revenue of $103.6 million and $310 million for the fourth quarter and full year of 2024, respectively, representing approximately 250% growth year over year Obtained three additional patents from the United States Patent and Trademark Office (USPTO) for BRIUMVI, extending patent protection through 2042 BRIUMVI launched in Europe with our partner, Neuraxpharm, which is now commercially available in several additional countries in the European Union and United Kingdom BRIUMVI Data Presentations Presented five-year data from the open-label extension study of the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in adult patients with relapsing forms of multiple sclerosis (RMS) which demonstrated that 92% of patients were free from disability progression after five years of treatment, an annualized relapse rate of 0.02 during year 5 of treatment (equivalent to one relapse occurring every fifty years of patient treatment), and an overall safety profile that remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment. Presented data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with RMS which demonstrated that: Rapid 30-minute BRIUMVI infusions are well tolerated in over 80 patients with RMS, and RMS patients who were already B-cell depleted from a prior anti-CD20 therapy were able to switch directly to a full 450 mg dose of BRIUMVI administered in 1 hour, without a 150 mg initial dose, with 97% of infusions being completed without interruption or slowing. Rapid 30-minute BRIUMVI infusions are well tolerated in over 80 patients with RMS, and RMS patients who were already B-cell depleted from a prior anti-CD20 therapy were able to switch directly to a full 450 mg dose of BRIUMVI administered in 1 hour, without a 150 mg initial dose, with 97% of infusions being completed without interruption or slowing. Pipeline Launched a Phase 1 trial evaluating subcutaneous ublituximab in patients with relapsing forms of multiple sclerosis (MS) Enrolled patients with Myasthenia Gravis (MG) into a Phase 1 trial with subcutaneous ublituximab Entered into a global license agreement with Precision BioSciences, Inc. (Precision) for the development and commercialization of Precision’s allogeneic CD19 CAR T therapy program, azercabtagene zapreleucel (azer-cel), for the treatment of autoimmune disorders and launched a Phase 1 trial in primary progressive multiple sclerosis 2025 Financial Guidance Full Year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million Full year 2025 target operating expense of approximately $300 million (excluding non-cash compensation) 2025 Development Pipeline Anticipated Milestones Commence pivotal program of subcutaneous ublituximab Commence a pivotal program based on data from the ENHANCE trial with the goal of enhancing the patient experience on intravenous BRIUMVI Enroll participants into the ongoing trial evaluating BRIUMVI in autoimmune diseases outside of MS Enroll participants into the Phase 1 azer-cel trial in autoimmune disease, beginning with progressive forms of MS Present updated data at major medical conferences throughout the year Financial Results for Fourth Quarter and Full Year 2024 Product Revenue, net: Product revenue, net was approximately $107.3 million and $313.7 million for the three and twelve months ended December 31, 2024, respectively, compared to $43.1 million and $92.0 million for the three and twelve months ended December 31, 2023, respectively. Product revenue, net consists primarily of net product sales of BRIUMVI in the United States, which totaled $103.6 million and $310.0 million during the three and twelve months ended December 31, 2024, respectively. Also included in product revenue, net during the three months ended December 31, 2023 and 2024 is approximately $3.2 million and $3.7 million, respectively, for product sold to our partner Neuraxpharm to support the Ex-US commercialization of BRIUMVI. License, milestone, royalty and other revenue: License, milestone, royalty and other revenue was approximately $0.8 million and $15.3 million for the three and twelve months ended December 31, 2024, respectively, compared to $0.8 million and $141.7 million for the three and twelve months ended December 31, 2023, respectively. License, milestone, royalty and other revenue for the twelve months ended December 31, 2024, is predominantly comprised of a $12.5 million milestone payment under the Neuraxpharm Commercialization Agreement for the first key market commercial launch of BRIUMVI in the European Union (EU) which occurred in the first quarter of 2024. License, milestone, royalty and other revenue for the twelve months ended December 31, 2023 is predominantly comprised of recognition of the one-time $140.0 million non-refundable upfront payment under the Commercialization Agreement with Neuraxpharm. R&D Expenses: Total research and development (R&D) expense was approximately $23.9 million and $94.3 million for the three and twelve months ended December 31, 2024, respectively, compared to $17.4 million and $76.2 million for the three and twelve months ended December 31, 2023, respectively. The increase in R&D expense during the three and twelve months ended December 31, 2024 was primarily attributable to manufacturing and development costs incurred in connection with our ublituximab subcutaneous development work, as well as license and milestone expense related to the license agreement with Precision BioSciences, Inc., during the period. SG&A Expenses: Total selling, general and administrative (SG&A) expense was approximately $39.0 million and $154.3 million for the three and twelve months ended December 31, 2024, respectively, compared to $31.2 million and $122.7 million for the three and twelve months ended December 31, 2023, respectively. The increase in both periods was primarily due to other selling, general and administrative costs, including personnel and consultants, associated with the commercialization of BRIUMVI during the period ended December 31, 2024. Net Income (Loss): Net income was $23.3 million and $23.4 million for the three and twelve months ended December 31, 2024, respectively, compared to a net loss of ($14.4) million for the three months ended December 31, 2023 and net income of $12.7 million for the twelve months ended December 31, 2023, respectively. Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $311.0 million as of December 31, 2024. We anticipate that our cash, cash equivalents and investment securities as of December 31, 2024, combined with the projected revenues from BRIUMVI, will be sufficient to fund our business based on our current operating plan. CONFERENCE CALL INFORMATIONThe Company will host a conference call today, March 3, 2025, at 8:30 AM ET, to discuss the Company’s financial results from the fourth quarter and full year ended December 31, 2024. To participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live audio webcast will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. An audio recording of the conference call will also be available for a period of 30 days after the call. ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IVBRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses. BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and UK for the treatment of adult patients with RMS with active disease defined by clinical or imaging features. A list of authorized specialty distributors can be found at www.briumvi.com. IMPORTANT SAFETY INFORMATIONContraindications: BRIUMVI is contraindicated in patients with: Active Hepatitis B Virus infection A history of life-threatening infusion reaction to BRIUMVI WARNINGS AND PRECAUTIONS Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization. Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment. Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI-treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved. Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI. Hepatitis B Virus (HBV) Reactivation: HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HB surface antigen (HBsAg) and anti-HB tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment. Progressive Multifocal Leukoencephalopathy (PML): Although no cases of PML have occurred in BRIUMVI-treated MS patients, JC virus infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies. If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis. If PML is confirmed, treatment with BRIUMVI should be discontinued. Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines, at least 4 weeks and, whenever possible, at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy: In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted. Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is recommended in females of reproductive potential prior to each infusion. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose. Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy, until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections. Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit www.briumvi.com. The full Summary of Product Characteristics approved in the European Union (EU) for BRIUMVI can be found here Briumvi | European Medicines Agency (europa.eu). ABOUT BRIUMVI PATIENT SUPPORT in the U.S. BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at www.briumvipatientsupport.com. ABOUT MULTIPLE SCLEROSIS Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately 85% are initially diagnosed with RRMS.1,2 The majority of people who are diagnosed with RRMS will eventually transition to SPMS, in which they experience steadily worsening disability over time. Worldwide, more than 2.3 million people have a diagnosis of MS.1 ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. Cautionary StatementThis press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below. Such forward looking statements include but are not limited to statements regarding expectations for the timing and success of the commercialization and availability of BRIUMVI® (ublituximab-xiiy) for RMS in the United States, European Union, United Kingdom, or other Ex-US territories; anticipated healthcare professional (HCP) and patient acceptance and use of BRIUMVI for the approved indications; expectations of future revenue for BRIUMVI, expenses or profits; expectations for our pipeline products; and statements regarding the results of the ENHANCE or ULTIMATE I & II Phase 3 studies. Additional factors that could cause our actual results to differ materially include the following: the Company’s ability to maintain and continue to maintain a commercial infrastructure for BRIUMVI, and to successfully or in the timeframe projected, market and sell BRIUMVI; the risk that trends in prescriptions are not maintained or that prescriptions are not filled; the failure to obtain and maintain payor coverage; the risk that HCP interest in BRIUMVI will not be sustained; the risk that momentum in sales for BRIUMVI will not build during the course of the year; the risk that the commercialization of BRIUMVI does not continue to exceed expectations; the risk that our BRIUMVI revenue targets will not be achieved; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements, the potential for variation from the Company’s projections and estimates about the potential market for BRIUMVI due to a number of factors, including, further limitations that regulators may impose on the required labeling for BRIUMVI (such as modifications, resulting from safety signals that arise in the post-marketing setting or in the long-term extension study from the ULTIMATE I and II clinical trials); the Company’s ability to meet post-approval compliance obligations (on topics including but not limited to product quality, product distribution and supply chain, pharmacovigilance, and sales and marketing); the Company’s reliance on third parties for manufacturing, distribution and supply, and other support functions for our clinical and commercial products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; potential regulatory challenges to the Company’s plans to seek marketing approval for the product in jurisdictions outside of the U.S.; the uncertainties inherent in research and development; the risk that any individual patient’s clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials such as ULTIMATE I and II; the risk that the Company does not achieve its 2025 development pipeline anticipated milestones in the timeframe projected or at all, including commencing a pivotal program for subcutaneous ublituximab, commencing a pivotal program based on data from the ENHANCE trial, enrolling patients into a trial evaluating BRIUMVI in an autoimmune disease outside of MS, or enrolling patients into a trial evaluating azer-cel; and general political, economic and business conditions. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 or December 31, 2022 and in our other filings with the SEC. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.CONTACT: Investor RelationsEmail:ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4 Media Relations:Email:media@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 6 1. MS Prevalence. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Datamonitor p. 236.

关注并星标CPHI制药在线 赛诺菲于近日公布2024年业绩，其拳头产品度普利尤单抗（商品名：达必妥）以141.79亿美元销售额成功卫冕"自免药王"。自免领域已成为继肿瘤之后，各大药企必争之地。对于赛诺菲来说，除了度普利尤单抗，还有哪些自免后备军？ 不断解锁炎症地图的自免新药王 度普利尤单抗（Dupilumab）是一种由赛诺菲与再生元合作开发的一款人源化单抗，通过结合 IL-4Rα，可同时阻断 IL-4 和 IL-13 信号通路，从而阻断 Th2 型炎症通路，减轻 Th2 型炎症的病理性反应，治疗 Th2 型炎症相关疾病。2017年，度普利尤单抗获FDA批准，用于治疗成人中重度特应性皮炎，成为首个获批上市的抗IL-4Rα抗体。 度普利尤单抗上市后不断解锁炎症新地图，目前在全球范围内，已获批多种适应症，包括涵盖各年龄段患者的特应性皮炎、12 岁及以上青少年和成人哮喘、慢性鼻窦炎伴鼻息肉（CRSwNP）、嗜酸性粒细胞性食管炎（EoE）、结节性痒疹、慢性自发性荨麻疹（CSU）以及慢阻肺病（COPD）等。 其中COPD适应症的获批尤其值得一提。COPD是一种会损伤肺部并导致肺功能逐渐下降的呼吸系统疾病。临床表现为持续性咳嗽、呼吸急促和黏液分泌过多，这些症状可能导致患者焦虑、抑郁和睡眠障碍，严重影响患者的生活质量。 在度普利尤单抗获批之前，COPD的治疗主要以支气管舒张剂和抗炎药物为主，这类传统治疗方式只能在一定程度上缓解症状，减缓疾病进程，并不能解决COPD急性加重反复发生的风险，该领域仍面临急迫的临床需求。 2024年7月，度普利尤单抗率先获欧洲药品管理局（EMA）批准作为一种附加维持治疗，用于血嗜酸性粒细胞升高且控制不佳的COPD成年人患者，成为首个用于治疗 COPD 的生物靶向药。 在一项评估度普利尤单抗在中重度 COPD 患者中的疗效和安全性的III期临床试验 BOREAS 的结果显示：52 周内中重度 COPD 的急性发作减少了 30% (p=0.0005)。第 12 周时度普利尤单抗治疗组患者 FEV1 较基线提高 160 mL，而安慰剂组对应数值为 77 mL (p<0.0001)。此外，BOREAS 研究治疗达到了所有次要终点。 在评估度普利尤单抗辅助治疗症状无法控制的 COPD 成人患者的疗效的III期临床试验 NOTUS 中：普利尤单抗在 52 周内将疾病恶化降低 34%。第 12 周时，度普利尤单抗治疗组患者肺功能较基线提高 139 mL，安慰剂组为 57 mL（p=0.0001），益处持续到第 52 周，度普利尤单抗组为 115 mL，安慰剂组为 54 mL（p=0.0182）。 结果显示了度普利尤单抗能够显著降低急性加重风险，改善了患者的肺功能，并提升了与健康相关的生活质量。 除以上获批适应症外，赛诺菲还在深度挖掘度普利尤单抗对其它2型炎症性疾病的应用潜力，例如大疱性类天疱疮（BP）、慢性特发性荨麻疹（CIU）、过敏性支气管肺曲霉病（ABPA）等。 随着度普利尤单抗不断开疆拓土，其销售额逐年攀升。2017年其销售额仅2亿欧元，但2019年销售额就达到21亿欧元，短短两年销售额翻了10倍。2024年上半年，度普利尤单抗销售额进一步上升至约66.6亿美元，超越艾伯维的阿达木单抗（2024上半年销售额50.84亿美元）、强生的乌司奴单抗（2024上半年销售额53.36亿美元），年末更是以23.1%的增速达到141.79亿美元，成为新一代自免药王。 赛诺菲的自免版图 赛诺菲在自免领域已形成成套的产品矩阵和梯队式的产品体系。目前，赛诺菲商业化产品还包括两款多发性硬化症（MS）产品Aubagio、Lemtrada，两款潜力产品IL-6单抗Kevzara和靶向补体C1s单抗Enjaymo。 还有峰值销售潜力有望达到20亿至50亿欧元的在研产品，包括治疗多发性硬化的Tolebrutinib和Rilzabrutinib、治疗哮喘的Lunsekimig、治疗炎症性肠病的TL1A单抗TEV'574、治疗特应性皮炎的IRAK4降解剂和治疗COPD的Itepekimab等。 Tolebrutinib是一款能够穿过血脑屏障的口服ＢＴＫ抑制剂，是赛诺菲于２０２１年以３７亿美元收购Principia Biopharma时获得。该药物可与小胶质细胞中的BTK结合，阻止小胶质细胞的活化，并且减少小胶质细胞释放的促炎因子，还可以通过抑制B细胞的增殖、成熟、自身抗体与细胞因子的产生以及抗原呈递和T细胞共刺激，调节位于外周与中枢神经系统的B细胞功能。 通过该双重机制，tolebrutinib可在外周和ＣＮＳ发挥疗效，阻止多发性硬化症的复发。 在治疗多发性硬化症的HERCULES　Ⅲ期研究中，tolebrutinib达到了主要终点--与安慰剂相比，该药物可以有效延缓残疾进展。结果表明，与安慰剂相比，tolebrutinib将6个月确诊残疾进展（CDP）的发作时间延迟了31%（HR 0.69;95% CI 0.55-0.88;p=0.0026）。值得注意的是，这是首个也是唯一一个显示非复发继发性进展型ＭＳ残疾积累减少的研究。 Lunsekimig是一款靶向TSLP／IL-13的纳米抗体，其体积较小，只有传统单克隆抗体的十分之一；并且与传统单克隆抗体相比，与人类重链可变结构域具有较高的序列同源性，临床副作用可能更少。凭借独特的纳米抗体结构和多结合位点的优势，Lunsekimig可同时阻断炎症上下游通路，有望带来更好的抗炎效果。 在分为3个部分的I期临床试验中，第1部分和第3部分的结果显示，Lunsekimig在健康成人中耐受性和安全性良好，免疫原性无临床意义。 第2部分的结果显示，相较于安慰剂，单剂量Lunsekimig（400 mg）治疗哮喘患者，第1周即快速降低FeNO（呼出气一氧化氮），第4周时FeNO显著降低达40.9 ppb（90%CI：-55.43，-26.39）。 结果提示，Lunsekimig或可更好地抑制气道炎症、早期改善肺功能和小气道功能障碍，且安全性和耐受性良好，进一步证实了Lunsekimig的临床应用潜力。 KT-474是一款由赛诺菲/Kymera Therapeutics共同开发的IRAK4降解剂，IRAK4是一种支架激酶，处于先天性免疫反应与适应性免疫反应的交汇点，通过其激酶活性和支架功能执行多重作用。它通过白细胞介素-1（IL-1）和toll样受体（TLR）参与调控免疫反应的信号传导过程，这些信号通路的异常是多种炎症性疾病的潜在机制。 在针对特应性皮炎和化脓性汗腺炎患者中的I期临床试验中，KT-474在血液和活动性皮肤病变中具有强大的降解效果，最多降解超过90%的IRAK4。对抗炎症生物标志物的活性检测结果显示，KT-474能够广泛抑制促炎细胞因子和趋化因子，并具有良好的安全性。 赛诺菲以度普利尤单抗打头阵，并布局一系列潜力重磅药物，其在自免领域的版图已徐徐展开。 参考来源：        1.赛诺菲财报PPT        2.Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy. Retrieved July 9, 2024, from https://investors.kymeratx.com/news-releases/news-release-details/kymera-announces-expansion-kt-474-sar444656-hs-and-ad-phase-2.   3.Gauvreau GM, et al. Expert Opin Ther Targets. 2020;24(8):777-792.       扫码领取CPHI & PMEC China 2025展会门票 来源：CPHI制药在线 声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。 投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~